{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T09:02:45Z","timestamp":1784797365477,"version":"3.55.0"},"reference-count":50,"publisher":"SAGE Publications","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAD"],"published-print":{"date-parts":[[2023,3,21]]},"abstract":"<jats:p>Background: Suppressor of tumorgenicity 2 (ST2) is highly expressed in brain tissue and is a receptor for interleukin 33 (IL-33). ST2 exists in two forms, a transmembrane receptor (ST2L) and a soluble decoy receptor (sST2). IL-33 binds to ST2L, triggering downstream signaling pathways involved in amyloid plaque clearance. Conversely, sST2 binds competitively to IL-33, attenuating its neuroprotective effects. High sST2 levels have been reported in mild cognitive impairment (MCI) and Alzheimer\u2019s disease (AD), suggesting that the IL-33\/ST2 signaling pathway may be implicated in neurodegenerative diseases. Objective: To investigate plasma sST2 levels in controls and patients with MCI, AD, frontotemporal dementia (FTD), and Parkinson\u2019s disease (PD). Methods: Plasma sST2 levels were measured using ELISA in 397 subjects (91 HC, 46 MCI, 38 AD, 28 FTD, and 194 PD). Cerebrospinal fluid (CSF) levels of sST2 were measured in 22 subjects. Relationship between sST2 and clinical outcomes were analyzed. Results: Plasma sST2 levels were increased across all disease groups compared to controls, with highest levels seen in FTD followed by AD and PD. Dementia patients with higher sST2 had lower cross-sectional cognitive scores in Frontal Assessment Battery and Digit Span Backward. At baseline, PD-MCI patients had higher sST2, associated with worse attention. In the longitudinal PD cohort, higher sST2 significantly associated with decline in global cognition and visuospatial domains. Plasma sST2 levels correlated with CSF sST2 levels. Conclusion: Plasma sST2 is raised across neurodegenerative diseases and is associated with poorer cognition. Higher baseline sST2 is a potential biomarker of disease severity in neurodegeneration.<\/jats:p>","DOI":"10.3233\/jad-221072","type":"journal-article","created":{"date-parts":[[2023,2,7]],"date-time":"2023-02-07T11:33:03Z","timestamp":1675769583000},"page":"573-580","source":"Crossref","is-referenced-by-count":14,"title":["Plasma Soluble ST2 Levels Are Higher in Neurodegenerative Disorders and Associated with Poorer Cognition"],"prefix":"10.1177","volume":"92","author":[{"given":"Yi Jayne","family":"Tan","sequence":"first","affiliation":[{"name":"Department of Neurology, National Neuroscience Institute, Tan Tock Seng Hospital, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel","family":"Siow","sequence":"additional","affiliation":[{"name":"Ministry of Health Holdings, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seyed Ehsan","family":"Saffari","sequence":"additional","affiliation":[{"name":"Department of Neurology, National Neuroscience Institute, Tan Tock Seng Hospital, Singapore"},{"name":"Center for Quantitative Medicine, Duke-NUS Medical School, National University of Singapore, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon K.S.","family":"Ting","sequence":"additional","affiliation":[{"name":"Department of Neurology, Singapore General Hospital, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeng","family":"Li","sequence":"additional","affiliation":[{"name":"Neural Stem Cell Research Lab, Department of Research, National Neuroscience Institute, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nagaendran","family":"Kandiah","sequence":"additional","affiliation":[{"name":"Department of Neurology, National Neuroscience Institute, Tan Tock Seng Hospital, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louis C.S.","family":"Tan","sequence":"additional","affiliation":[{"name":"Department of Neurology, National Neuroscience Institute, Tan Tock Seng Hospital, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eng King","family":"Tan","sequence":"additional","affiliation":[{"name":"Center for Quantitative Medicine, Duke-NUS Medical School, National University of Singapore, Singapore"},{"name":"Neuroscience and Behavioural Disorders Unit, Duke-NUS Medical School, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adeline S.L.","family":"Ng","sequence":"additional","affiliation":[{"name":"Department of Neurology, National Neuroscience Institute, Tan Tock Seng Hospital, Singapore"},{"name":"Neuroscience and Behavioural Disorders Unit, Duke-NUS Medical School, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","reference":[{"key":"10.3233\/JAD-221072_ref1","doi-asserted-by":"crossref","unstructured":"Weller J , Budson A (2018) Current understanding of Alzheimer\u2019s disease diagnosis and treatment. F1000Res 7, F1000 Faculty Rev-1161.","DOI":"10.12688\/f1000research.14506.1"},{"key":"10.3233\/JAD-221072_ref2","first-page":"116","article-title":"Non-pharmacologic interventions for persons with dementia","volume":"114","author":"Berg-Weger","year":"2017","journal-title":"Mo Med"},{"key":"10.3233\/JAD-221072_ref3","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1212\/WNL.0000000000000610","article-title":"The global burden of neurologic diseases","volume":"83","author":"Chin","year":"2014","journal-title":"Neurology"},{"key":"10.3233\/JAD-221072_ref4","doi-asserted-by":"crossref","first-page":"5346413","DOI":"10.1155\/2018\/5346413","article-title":"Critical roles of IL-33\/ST2 pathway in neurological disorders","volume":"2018","author":"Abd Rachman Isnadi","year":"2018","journal-title":"Mediators Inflamm"},{"key":"10.3233\/JAD-221072_ref5","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1038\/nrd2660","article-title":"The IL-33\/ST2 pathway: Therapeutic target and novel biomarker","volume":"7","author":"Kakkar","year":"2008","journal-title":"Nat Rev Drug Discov"},{"key":"10.3233\/JAD-221072_ref6","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/j.neuron.2015.01.013","article-title":"The glia-derived alarmin IL-33 orchestrates the immune response and promotes recovery following CNS injury","volume":"85","author":"Gadani","year":"2015","journal-title":"Neuron"},{"key":"10.3233\/JAD-221072_ref7","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1186\/s40478-016-0344-1","article-title":"Role of IL-33 and ST2 signalling pathway in multiple sclerosis: Expression by oligodendrocytes and inhibition of myelination in central nervous system","volume":"4","author":"Allan","year":"2016","journal-title":"Acta Neuropathol Commun"},{"key":"10.3233\/JAD-221072_ref8","doi-asserted-by":"crossref","first-page":"E2705","DOI":"10.1073\/pnas.1604032113","article-title":"IL-33 ameliorates Alzheimer\u2019s disease-like pathology and cognitive decline","volume":"113","author":"Fu","year":"2016","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.3233\/JAD-221072_ref9","doi-asserted-by":"crossref","first-page":"297","DOI":"10.3233\/JAD-132081","article-title":"Alzheimer\u2019s disease: Evidence for the expression of interleukin-33 and its receptor ST2 in the brain","volume":"40","author":"Xiong","year":"2014","journal-title":"J Alzheimers Dis"},{"key":"10.3233\/JAD-221072_ref10","doi-asserted-by":"crossref","first-page":"7967","DOI":"10.1038\/ncomms8967","article-title":"Breaking immune tolerance by targeting Foxp3(+) regulatory T cells mitigates Alzheimer\u2019s disease pathology","volume":"6","author":"Baruch","year":"2015","journal-title":"Nat Commun"},{"key":"10.3233\/JAD-221072_ref11","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1186\/s12974-022-02605-9","article-title":"The role of the adaptive immune system and T cell dysfunction in neurodegenerative diseases","volume":"19","author":"DeMaio","year":"2022","journal-title":"J Neuroinflammation"},{"key":"10.3233\/JAD-221072_ref12","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1186\/s12967-022-03570-w","article-title":"Dual roles of interleukin-33 in cognitive function by regulating central nervous system inflammation","volume":"20","author":"Rao","year":"2022","journal-title":"J Transl Med"},{"key":"10.3233\/JAD-221072_ref13","doi-asserted-by":"crossref","first-page":"2596","DOI":"10.3389\/fimmu.2018.02596","article-title":"Expression and function of IL-33\/ST2 axis in the central nervous system under normal and diseased conditions","volume":"9","author":"Fairlie-Clarke","year":"2018","journal-title":"Front Immunol"},{"key":"10.3233\/JAD-221072_ref14","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/j.cell.2020.05.050","article-title":"Microglial remodeling of the extracellular matrix promotes synapse plasticity","volume":"182","author":"Nguyen","year":"2020","journal-title":"Cell"},{"key":"10.3233\/JAD-221072_ref15","doi-asserted-by":"crossref","first-page":"e2020810118","DOI":"10.1073\/pnas.2020810118","article-title":"Astrocyte-secreted IL-33 mediates homeostatic synaptic plasticity in the adult hippocampus","volume":"118","author":"Wang","year":"2021","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.3233\/JAD-221072_ref17","doi-asserted-by":"crossref","first-page":"107530","DOI":"10.1016\/j.celrep.2020.107530","article-title":"IL-33-PU.1 transcriptome reprogramming drives functional state transition and clearance activity of microglia in Alzheimer\u2019s disease","volume":"31","author":"Lau","year":"2020","journal-title":"Cell Rep"},{"key":"10.3233\/JAD-221072_ref18","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1186\/s12974-020-01806-4","article-title":"IL-33 and its decoy sST2 in patients with Alzheimer\u2019s disease and mild cognitive impairment","volume":"17","author":"Saresella","year":"2020","journal-title":"J Neuroinflammation"},{"key":"10.3233\/JAD-221072_ref19","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/s13195-020-00652-z","article-title":"The role of interleukin-33 in patients with mild cognitive impairment and Alzheimer\u2019s disease","volume":"12","author":"Liang","year":"2020","journal-title":"Alzheimers Res Ther"},{"key":"10.3233\/JAD-221072_ref20","doi-asserted-by":"crossref","first-page":"16760","DOI":"10.1038\/s41598-017-16754-y","article-title":"Immune and imaging correlates of mild cognitive impairment conversion to Alzheimer\u2019s disease","volume":"7","author":"La Rosa","year":"2017","journal-title":"Sci Rep"},{"key":"10.3233\/JAD-221072_ref21","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1001\/archneur.56.3.303","article-title":"Mild cognitive impairment: Clinical characterization and outcome","volume":"56","author":"Petersen","year":"1999","journal-title":"Arch Neurol"},{"key":"10.3233\/JAD-221072_ref22","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.jalz.2011.03.005","article-title":"The diagnosis of dementia due to Alzheimer\u2019s disease: Recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease","volume":"7","author":"McKhann","year":"2011","journal-title":"Alzheimers Dement"},{"key":"10.3233\/JAD-221072_ref23","doi-asserted-by":"crossref","first-page":"145","DOI":"10.3109\/09540261.2013.763341","article-title":"Clinical diagnostic criteria and classification controversies in frontotemporal lobar degeneration","volume":"25","author":"Rascovsky","year":"2013","journal-title":"Int Rev Psychiatry"},{"key":"10.3233\/JAD-221072_ref24","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1001\/archneur.56.1.33","article-title":"Diagnostic criteria for Parkinson disease","volume":"56","author":"Gelb","year":"1999","journal-title":"Arch Neurol"},{"key":"10.3233\/JAD-221072_ref25","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1111\/j.1532-5415.2005.53221.x","article-title":"The Montreal Cognitive Assessment, MoCA: A brief screening tool for mild cognitive impairment","volume":"53","author":"Nasreddine","year":"2005","journal-title":"J AM Geriatr Soc"},{"key":"10.3233\/JAD-221072_ref26","first-page":"627","article-title":"Alzheimer\u2019s Disease Assessment Scale (ADAS)","volume":"24","author":"Mohs","year":"1988","journal-title":"Psychopharmacol Bull"},{"key":"10.3233\/JAD-221072_ref27","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1212\/WNL.55.11.1621","article-title":"The FAB: A Frontal Assessment Battery at bedside","volume":"55","author":"Dubois","year":"2000","journal-title":"Neurology"},{"key":"10.3233\/JAD-221072_ref28","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1080\/09084280802644466","article-title":"Wechsler Adult Intelligence Scale IV (WAIS IV): Return of the gold standard","volume":"16","author":"Hartman","year":"2009","journal-title":"Appl Neuropsychol"},{"key":"10.3233\/JAD-221072_ref30","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1038\/nprot.2006.115","article-title":"Clinical and empirical applications of the Rey-Osterrieth Complex Figure Test","volume":"1","author":"Shin","year":"2006","journal-title":"Nat Protoc"},{"key":"10.3233\/JAD-221072_ref31","doi-asserted-by":"crossref","first-page":"P154","DOI":"10.1093\/geronj\/47.3.P154","article-title":"Boston Naming Test: Shortened versions for use in Alzheimer\u2019s disease","volume":"47","author":"Mack","year":"1992","journal-title":"J Gerontol"},{"key":"10.3233\/JAD-221072_ref32","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1111\/ene.14192","article-title":"Periventricular white matter hyperintensity burden and cognitive impairment in early Parkinson\u2019s disease","volume":"27","author":"Huang","year":"2020","journal-title":"Eur J Neurol"},{"key":"10.3233\/JAD-221072_ref33","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1002\/mds.24893","article-title":"Diagnostic criteria for mild cognitive impairment in Parkinson\u2019s disease: Movement Disorder Society Task Force guidelines","volume":"27","author":"Litvan","year":"2012","journal-title":"Mov Disord"},{"key":"10.3233\/JAD-221072_ref34","doi-asserted-by":"crossref","first-page":"493","DOI":"10.3233\/JPD-130250","article-title":"The role of innate and adaptive immunity in Parkinson\u2019s disease","volume":"3","author":"Kannarkat","year":"2013","journal-title":"J Parkinsons Dis"},{"key":"10.3233\/JAD-221072_ref35","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1038\/s41582-021-00579-5","article-title":"Publisher correction: Peripheral and central immune system crosstalk in Alzheimer disease \u2014a research prospectus","volume":"17","author":"Bettcher","year":"2021","journal-title":"Nat Rev Neurol"},{"key":"10.3233\/JAD-221072_ref36","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1186\/s12974-018-1169-6","article-title":"IL-33\/ST2 plays a critical role in endothelial cell activation and microglia-mediated neuroinflammation modulation","volume":"15","author":"Cao","year":"2018","journal-title":"J Neuroinflammation"},{"key":"10.3233\/JAD-221072_ref37","doi-asserted-by":"crossref","first-page":"813951","DOI":"10.3389\/fimmu.2022.813951","article-title":"IL-33 and IL-10 serum levels increase in MCI patients following homotaurine treatment","volume":"13","author":"Toppi","year":"2022","journal-title":"Front Immunol"},{"key":"10.3233\/JAD-221072_ref38","doi-asserted-by":"crossref","DOI":"10.1177\/26331055211030251","article-title":"Role of Interleukin33 in rejuvenation of aged neurons and age-related dementias","volume":"16","author":"Lou","year":"2021","journal-title":"J Exp Neurosci"},{"key":"10.3233\/JAD-221072_ref39","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/j.cytogfr.2015.07.017","article-title":"The IL-33\/ST2 axis: Role in health and disease","volume":"26","author":"De la Fuente","year":"2015","journal-title":"Cytokine Growth Factor Rev"},{"key":"10.3233\/JAD-221072_ref40","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1038\/mp.2009.10","article-title":"Transcriptomic and genetic studies identify IL-33 as a candidate gene for Alzheimer\u2019s disease","volume":"14","author":"Chapuis","year":"2009","journal-title":"Mol Psychiatry"},{"key":"10.3233\/JAD-221072_ref41","doi-asserted-by":"crossref","first-page":"1014.e11","DOI":"10.1016\/j.neurobiolaging.2010.07.003","article-title":"Implication of IL-33 gene polymorphism in Chinese patients with Alzheimer\u2019s disease","volume":"33","author":"Yu","year":"2012","journal-title":"Neurobiol Aging"},{"key":"10.3233\/JAD-221072_ref42","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.brainres.2014.11.019","article-title":"Association of IL-1, IL-18, and IL-33 gene polymorphisms with late-onset Alzheimer\u2019s disease in a hunan Han Chinese population","volume":"1596","author":"Tian","year":"2015","journal-title":"Brain Res"},{"key":"10.3233\/JAD-221072_ref43","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1038\/nri2692","article-title":"Disease-associated functions of IL-33: The new kid in the IL-1 family","volume":"10","author":"Liew","year":"2010","journal-title":"Nat Rev Immunol"},{"key":"10.3233\/JAD-221072_ref44","doi-asserted-by":"crossref","first-page":"e1164","DOI":"10.1038\/tp.2017.142","article-title":"Interleukin33 deficiency causes tau abnormality and neurodegeneration with Alzheimer-like symptoms in aged mice","volume":"7","author":"Carlock","year":"2017","journal-title":"Transl Psychiatry"},{"key":"10.3233\/JAD-221072_ref45","doi-asserted-by":"crossref","first-page":"315","DOI":"10.3390\/medicina57040315","article-title":"IL-33 in Mental Disorders","volume":"57","author":"Pandolfo","year":"2021","journal-title":"Medicina (Kaunas)"},{"key":"10.3233\/JAD-221072_ref46","first-page":"2017","article-title":"Behavioral changes in mice lacking Interleukin-33. , ENEURO.0147-17","volume":"4","author":"Dohi","year":"2017","journal-title":"eNeuro"},{"key":"10.3233\/JAD-221072_ref47","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1007\/s13311-020-00963-x","article-title":"Approach to cognitive impairment in Parkinson\u2019s disease","volume":"17","author":"Zhang","year":"2020","journal-title":"Neurotherapeutics"},{"key":"10.3233\/JAD-221072_ref48","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/s41572-021-00280-3","article-title":"Parkinson disease-associated cognitive impairment","volume":"7","author":"Aarsland","year":"2021","journal-title":"Nat Rev Dis Primers"},{"key":"10.3233\/JAD-221072_ref49","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1038\/s41531-022-00375-y","article-title":"Biomarker characterization of clinical subtypes of Parkinson Disease","volume":"8","author":"Deng","year":"2022","journal-title":"NPJ Parkinsons Dis"},{"key":"10.3233\/JAD-221072_ref50","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1111\/j.1440-1789.2007.00803.x","article-title":"The Lewy body in Parkinson\u2019s disease: Molecules implicated in the formation and degradation of \u03b1-synuclein aggregates","volume":"27","author":"Wakabayashi","year":"2007","journal-title":"Neuropathology"},{"key":"10.3233\/JAD-221072_ref51","doi-asserted-by":"crossref","first-page":"654626","DOI":"10.3389\/fimmu.2021.654626","article-title":"Therapeutic opportunities of Interleukin-33 in the central nervous system","volume":"12","author":"Sun","year":"2021","journal-title":"Front Immunol"},{"key":"10.3233\/JAD-221072_ref52","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1007\/s12035-018-1177-7","article-title":"Mast cell proteases activate astrocytes and glia-neurons and release Interleukin-33 by activating p38 and ERK1\/2 MAPKs and NF-\u03baB","volume":"56","author":"Kempuraj","year":"2019","journal-title":"Mol Neurobiol"}],"container-title":["Journal of Alzheimer's Disease"],"original-title":[],"link":[{"URL":"https:\/\/content.iospress.com\/download?id=10.3233\/JAD-221072","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T10:07:17Z","timestamp":1777370837000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/full\/10.3233\/JAD-221072"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,21]]},"references-count":50,"journal-issue":{"issue":"2"},"URL":"https:\/\/doi.org\/10.3233\/jad-221072","relation":{},"ISSN":["1387-2877","1875-8908"],"issn-type":[{"value":"1387-2877","type":"print"},{"value":"1875-8908","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,21]]}}}